Navigation Links
Survey highlights support for nanotech in health fields but disapproval elsewhere
Date:11/13/2008

A landmark national survey on the use of nanotechnology for "human enhancement" shows widespread public support for applications of the new technology related to improving human health. However, the survey also shows broad disapproval for nanotech human enhancement research in areas without health benefits. A team of researchers at North Carolina State University and Arizona State University (ASU) conducted the study, which could influence the direction of future nanotechnology research efforts.

The "Public Awareness of Nanotechnology Study" is the first nationally representative survey to examine public opinion on the use of nanotechnology for human enhancement. The survey found significant support for enhancements that promise to improve human health. For example, 88 percent of participants were in favor of research for a video-to-brain link that would amount to artificial eyesight for the blind. However, there was little support for non-health research endeavors. For example, only 30 percent of participants approved of research into implants that could improve performance of soldiers on the battlefield.

Nanotechnology is generally defined as technology that uses substances having a size of 100 nanometers or less (tens of thousands of times smaller than the width of a human hair), and is expected to have widespread uses in medicine, consumer products and industrial processes. Human enhancement is a sweeping term that applies to the use of such technologies to alter human capabilities.

NC State's Dr. Michael Cobb, one of the leaders of the study, says the survey's findings are important because "what the public wants could drive the direction of future research." Cobb, an associate professor of political science, explains, "The public should have input into where the government invests its research funding." Dr. Clark Miller, an associate professor of political science at ASU and another leader of the survey, adds, "One of the most i
'/>"/>

Contact: Matt Shipman
matt_shipman@ncsu.edu
919-515-6386
North Carolina State University
Source:Eurekalert

Page: 1 2

Related biology news :

1. St. Jude influenza survey uncovers key differences between bird flu and human flu
2. Survey finds elevated rates of new asthma among WTC rescue and recovery workers
3. Misconceptions about Alzheimers varies among races, survey suggests
4. Americans remain pessimistic about the environment, Stanford-AP survey finds
5. Single-largest biodiversity survey says primary rainforest is irreplaceable
6. Widespread support for nonembryonic stem cell research, VCU Life Sciences Survey shows
7. Skull survey could improve vehicle safety
8. Ecological genetics of freshwater bacteria surveyed
9. Unmanned aerial vehicles mark robotic first for British Antarctic Survey
10. Smithsonian coral biodiversity survey of Panamas Pearl Islands
11. Survey of Hispanics and alcohol dependence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... Conn. , Apr. 1, 2015  NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... of Wocket smart wallets is underway to early access ... access group includes usage at retail outlets including Walmart, ... Pharmacy. Users report Wocket was accepted at all outlets ...
(Date:3/31/2015)... YORK , March 31, 2015   Guidepoint ... the launch of the Post-Surgical Pain Management TRACKER, part ... products tracking usage trends in the medical device and ... access to data including treatment volumes, market share, and ... the pain associated with joint surgery. The ...
(Date:3/24/2015)... Mar. 24, 2015 Research and Markets ... "Global Iris Recognition Market 2015-2019" report to ... Iris Recognition market to grow at a CAGR of ... report covers the present scenario and the growth prospects ... 2015-2019. To calculate the market size, the report considers ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... ARTICLE #1 FOR IMMEDIATE RELEASE Evidence that inexpensive ... Energy & Fuels Amid sticker-shock fuel prices, researchers ... tests verifying that a simple, inexpensive device attached to a ... to 20 percent. That translates into several more precious miles ...
... They are used in cancer treatments, automobile sensors, ... production. However, until recently, scientists couldn,t create the ... impacts on the environment. A new method, created ... only eliminates any negative environmental impact, but also ...
... and his collaborators have developed a way to mass-produce ... less expensive. Metcalf set out to ... as phosphonates, is made in nature by bacteria. He ... have antibiotic properties. Recently, Metcalf and his lab successfully ...
Cached Biology News:American Chemical Society's Weekly PressPac -- Sept. 24, 2008 2American Chemical Society's Weekly PressPac -- Sept. 24, 2008 3American Chemical Society's Weekly PressPac -- Sept. 24, 2008 4American Chemical Society's Weekly PressPac -- Sept. 24, 2008 5American Chemical Society's Weekly PressPac -- Sept. 24, 2008 6American Chemical Society's Weekly PressPac -- Sept. 24, 2008 7American Chemical Society's Weekly PressPac -- Sept. 24, 2008 8MU scientists go green with gold, distribute environmentally friendly nanoparticles 2New way to make malaria medicine also first step in finding new antibiotics 2New way to make malaria medicine also first step in finding new antibiotics 3New way to make malaria medicine also first step in finding new antibiotics 4
(Date:4/23/2015)... April 23, 2015 Proove ... Personalized Medicine, is excited to announce the launch ... . This profile assesses 62 genetic variations to ... information for commonly prescribed non-opioid pain medications, namely ... Neurontin), alprazolam (brand name Xanax) and acetaminophen (brand ...
(Date:4/23/2015)... NY , April 23, 2015 /PRNewswire/ - Crystal ... an Executive Informational Overview ® (EIO) on Aeterna ... 52-page report is available on Crystal Research Associates, website ... on Aeterna Zentaris, website at www.aezsinc.com . ... into a specialty biopharmaceutical company in oncology, endocrinology, and ...
(Date:4/22/2015)... 23, 2015  The Heinz Family Foundation today ... Heinz Awards, which will present unrestricted cash awards ... their creativity and determination in finding solutions to ... This year,s recipients include a prolific cartoonist whose ... and personal relationships; two former Marines who are ...
(Date:4/22/2015)... 2015   MPIRICA Health Inc. , a ... Series A financing from the McQuinn Trust, an ... consumer and employer awareness of MPIRICA.com, delivering easily ... 4,800 U.S. hospitals. "As a patient ... concerned about choosing the hospital and surgeon most ...
Breaking Biology Technology:Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 2Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 3Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Aeterna Zentaris Inc. 2Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Aeterna Zentaris Inc. 3From a Scientist Who Develops Human Microlivers to a New Yorker Cartoonist Who Masterfully Depicts the Humor and Heartbreak of Everyday Life: The 20th Heinz Awards Honors Six Changemakers 2From a Scientist Who Develops Human Microlivers to a New Yorker Cartoonist Who Masterfully Depicts the Humor and Heartbreak of Everyday Life: The 20th Heinz Awards Honors Six Changemakers 3From a Scientist Who Develops Human Microlivers to a New Yorker Cartoonist Who Masterfully Depicts the Humor and Heartbreak of Everyday Life: The 20th Heinz Awards Honors Six Changemakers 4From a Scientist Who Develops Human Microlivers to a New Yorker Cartoonist Who Masterfully Depicts the Humor and Heartbreak of Everyday Life: The 20th Heinz Awards Honors Six Changemakers 5From a Scientist Who Develops Human Microlivers to a New Yorker Cartoonist Who Masterfully Depicts the Humor and Heartbreak of Everyday Life: The 20th Heinz Awards Honors Six Changemakers 6MPIRICA Health Inc. Secures $1.6M to Promote FICO-Like Quality Scores for Surgeries 2
... capable of some pretty remarkable things when they,re placed ... can even produce electricity. Driven by the vision ... team of University of Houston scientists has set out ... known as piezoelectrics, which naturally produce electricity when literally ...
... , , , ... Inc. (NYSE: BEC ) announced today that its Board of ... of outstanding common stock, payable on August 24, 2009 to all stockholders ... consecutive, quarterly payout of dividends. , , (Logo: ...
... , , ... Amgen (Nasdaq: AMGN ) and GlaxoSmithKline (GSK) today announced ... monoclonal antibody denosumab for postmenopausal osteoporosis (PMO) in Europe, Australia, New ... Amgen will commercialize the drug for PMO and oncology in ...
Cached Biology Technology:Charging ahead: University of Houston team revealing secrets of electricity-producing materials 2Charging ahead: University of Houston team revealing secrets of electricity-producing materials 3Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 2Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 3Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 4Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 5Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 6Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 7
... Biotin label transfer is fast emerging ... interaction discovery and confirmation. Until now, only ... targeted with label transfer reagents such as ... chain analog, Mts-Atf-LC-Biotin, are exciting additions to ...
... of 3 siRNAs specifically targeted to your ... product. The siTrio reagent guarantees you get ... gene when used under standard conditions (100 ... optimal transfection with one of B-Bridges controls). ...
... a compact benchtop and stackable multi-function ... with a large display screen to ... Air circulation inside to evenly distribute ... be easily calibrated from the microprocessor ...
...
Biology Products: